Physician profile
Jordan E Scott
NPI 1275517245
$12,838.22
in general payments reported to CMS, 2019-2025
40 companies · $2,986 in 2025
The $2,986 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $603 · 2021: $626 · 2022: $1,613 · 2023: $2,829 · 2024: $3,318 · 2025: $2,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,890 · Education: $228 · Consulting Fee: $15.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,889.84 |
| Education | $228.36 |
| Consulting Fee | $15.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,971.32 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,614.65 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,586.56 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $853.63 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $695.17 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Abbvie INC. | $649.88 | 2022-2024 | Rinvoq |
| Pfizer INC. | $600.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $537.97 | 2019-2025 | |
| Pharming Healthcare, INC. | $533.43 | 2022-2025 | Ruconest |
| Genzyme Corporation | $504.86 | 2019-2025 | |
| Blueprint Medicines Corporation | $345.15 | 2023-2024 | Ayvakit |
| Kaleo, INC. | $220.87 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $187.25 | 2022-2025 | Orladeyo |
| Genentech USA, INC. | $152.25 | 2019-2025 | Xolair |
| Amgen INC. | $133.45 | 2023-2025 | Tezspire, Actimmune |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $116.71 | 2020-2022 | |
| Gc Biopharma USA, INC. | $105.71 | 2025 | Alyglo |
| Teva Pharmaceuticals USA, INC. | $89.82 | 2019-2021 | |
| Lilly USA, LLC | $80.75 | 2024-2025 | Ebglyss, Taltz |
| Invivyd INC | $79.32 | 2025 | Pemgarda |
| Ars Pharmaceuticals Operations, INC. | $78.53 | 2025 | Neffy |
| Grifols USA, LLC | $77.25 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Alk-Abello, INC | $68.60 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Horizon Therapeutics Plc | $63.05 | 2021-2023 | Actimmune |
| Leo Pharma INC. | $58.44 | 2022-2023 | Adbry |
| Bio Products Laboratory USA, INC. | $50.44 | 2022-2023 | Gammaplex, Coagadex |
| Mylan Specialty L.P. | $45.14 | 2020-2021 | |
| Kedrion Biopharma, INC. | $40.13 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.18 | 2019-2021 | |
| Optinose US, INC. | $37.16 | 2021-2022 | |
| Circassia INC. | $31.63 | 2019-2021 | |
| Cycle Pharmaceuticals INC | $30.82 | 2024 | Sajazir |
| Galderma Laboratories, L.P. | $28.01 | 2025 | Nemluvio |
| Shire North American Group INC | $22.93 | 2019 | |
| Incyte Corporation | $21.40 | 2022 | |
| Covis Pharma Gmbh | $19.36 | 2022 | |
| Arcutis Biotherapeutics, INC. | $18.76 | 2025 | Zoryve |
| Phadia US INC. | $16.06 | 2023 | Immunocap |
| Adma Biomanufacturing LLC | $15.95 | 2023 | |
| Inspire Medical Systems, INC. | $15.85 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.